Shares of Oncolytics Biotech jumped 8.9% to $0.42 after the company unveiled new translational data at the SITC 2026 Annual Meeting showing its experimental virus-based therapy can awaken the immune system against HPV-driven anal cancer — a potentially important proof point for a company valued at roughly $51 million that is trying to fight its way into a multi-billion-dollar market.
• Seven Out of Eight Patients Showed Strong Immune Responses, Giving the Science Real Numbers. In seven of eight evaluable patients, immune-activation biomarkers more than doubled after just one treatment cycle.
After three cycles, all four evaluable patients showed expansion of cancer-fighting immune cell clones, which was associated with tumor reductions — including two complete responses and two partial responses. These are small patient numbers, but the consistency matters: it suggests the drug is doing what the company claims, training the body's immune system to recognize and attack HPV-infected tumor cells.
• The Combination Already Looks Better Than the Only Approved Alternative. The combination of Oncolytics' therapy with a checkpoint inhibitor produced an objective response rate more than twice that of the current approved therapy and a 50% increase in median response duration.
Updated GOBLET data showed approximately 15-month median response duration, versus 9.5 months for the approved competitor. If that gap holds up in a larger trial, it would represent a meaningful advance in a cancer with very limited options.
• FDA Alignment on a Pivotal Trial Opens a Path — but the Bill Comes Next. In April 2026, Oncolytics announced alignment with the FDA on the design of a pivotal randomized study in anal cancer.
As of March 31, 2026, the company had just $5.5 million in cash.
It has since established a $75 million at-the-market stock offering facility with Jefferies — meaning it can sell new shares to raise money, but at today's depressed price that means significant dilution for existing shareholders.
• The Real Prize Is Bigger Than Anal Cancer. Management estimates the broader HPV-associated cancer market at $3 billion to $5 billion.
CEO Jared Kelly has called anal cancer "the starting point" for building a platform across HPV-driven cancers, including head and neck tumors where the drug has also shown early activity. The company has secured patent protection into the late 2040s. The strategic logic is sound, but execution depends entirely on funding a pivotal trial that this micro-cap cannot currently afford on its own — making a partnership or acquisition the most likely path forward.